Replies to post #354982 on Amarin Corp Plc (AMRN)

[Whalatane]

PD. Im not sure Im concerned ...more just trying to understand where we are going re Covid

Let me try it this way

Assuming most of us get vaccinated then our concern is not so much about hospitalization and death ( as thats happening far more with those unvaccinated ) .....its our recovery time if we get a break through infection .

Since Covid booster shots are currently being limited to those over 65 in the US ...we are likely to see more break thru infections as the protection from the current vaccines wane over time.

So the question is which drug ...in this case oral drug ...will shorten our recovery time ... AT527 , Vascepa or Molnupiravir .
Molnupiravir inclusion requirements raises question ...and theres an obvious concern re liver damage in their exclusion criteria .
AT527 does appear to short recovery time in the data seen so far

Will we have the same kind of data ( difference in recovery times / viral load etc ) from P-IT 2 ?

Kiwi

[Whalatane]

Simply put ...Since P-IT 2 is a trial on non hospitalized patients diagnosed with Covid ....IF none in either arm end up being hospitalized ...will be know if those in the V arm recovered faster ?

Kiwi